Korean J Urol.  2008 Sep;49(9):765-774.

Recent Concepts of Premature Ejaculation

• Ham WS
• Kim WT
• Choi HK
• Choi YD

Abstract

Premature ejaculation(PE) is the most prevalent male sexual complaint, yet it remains underdiagnosed and undertreated. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin(5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation and pharmacologic manipulation of the serotonergic system has been performed in rats, with the antidepressant selective serotonin reuptake inhibitors(SSRIs) exhibiting the greatest efficacy in delaying ejaculation. Over the last decade, an increasing number of studies of drug treatment of PE have been published. A meta-analysis of those studies demonstrated similar efficacies for daily treatment with the serotonergic antidepressants paroxetine hemihydrate, clomipramine, sertraline and fluoxetine, with paroxetine(hydrochloride) hemihydrate exerting the strongest effect on ejaculation. On the basis of fundamental insights into serotonergic neurotransmission, it has been suggested that on-demand selective serotonin reuptake inhibitor(SSRI) treatment will not lead to similarly impressive delays in ejaculation as has been observed with daily SSRI treatment. Apart from daily treatment with SSRIs, PE can be delayed by on-demand use of topical anaesthetics. Treatment with phosphodiesterase type 5 inhibitors may be used if PE is accompanied by erectile difficulties.

Keyword

Premature ejaculation; Neurophysiology; Treatment; Selective serotonin reuptake inhibitor

MeSH Terms

Animals
Antidepressive Agents
Brain
Clomipramine
Ejaculation
Fluoxetine
Humans
Male
Neurophysiology
Paroxetine
Phosphodiesterase 5 Inhibitors
Premature Ejaculation
Rats
Serotonin
Sertraline
Spinal Cord
Synaptic Transmission
Antidepressive Agents
Clomipramine
Fluoxetine
Paroxetine
Phosphodiesterase 5 Inhibitors
Serotonin
Sertraline

Figure

• 

  Fig. 1 Schematic representation of the control of the seminal tract and the bulbospongiosus (BS) muscle by the spinal ejaculation generator (LSt cells) in rats. The spinal ejaculation generator projects to the parasympathetic sacral parasympathetic nucleus (SPN) and sympathetic dorsal grey commissure (DGC) and intermediolateral cell column (IML) preganglionic neurons, and BS muscle motoneurones (Onuf's nucleus). The parasympathetic centre projects to the seminal tract via the pelvic nerve (PN) and the major pelvic ganglion (MPG). The sympathetic centre innervates the seminal tract by sending projections through the lumbar sympathetic chain (LSC) to the superior hypogastric plexus (SHP) and then via the hypogastric nerve (HN), which joins the MPG. The motoneurones of the BS muscle project to the muscle through the motor branch of the pudendal nerve (PudN).13

• 

  Fig. 2 Diagram of brain structures and putative central pathways involved in ejaculation. Structures containing serotonin auto/heteroreceptors are indicated in grey. BNSTpm: posteromedial bed nucleus of stria terminalis, MeApd: posterodorsal medial amygdaloid nucleus, MPOA: medial preoptic area, PAG: periaqueductal grey, nPGi: paragigantocellular nucleus, PNpd: posterodorsal preoptic nucleus, PVN: paraventricular thalamic nucleus, SPFp: parvicellular part of the subparafascicular thalamus.13

Reference

1. McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol. 1998. 159:1935–1938.

2. Kuhr CS, Heiman J, Cardenas D, Bradley W, Berger RE. Premature emission after spinal cord injury. J Urol. 1995. 153:429–431.

3. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J Clin Psychopharmacol. 2003. 23:467–470.

4. Waldinger MD, Zwinderman AH, Olivier B. SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001. 21:556–560.

5. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol. 2001. 21:293–297.

6. Waldinger MD, Schweitzer DH. Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med. 2008. 5:966–997.

7. Choi HK, Jung GW, Moon KH, Xin ZC, Choi YD, Lee WH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology. 2000. 55:257–261.

8. Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation. J Urol. 1995. 154:1360–1361.

9. Waldinger MD, Schweitzer DH. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II-proposals for DSM-V and ICD-11. J Sex Med. 2006. 3:693–705.

10. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol. 2002. 168:2359–2367.

11. Bloom KK, Goldberg G. Tibial nerve somatosensory evoked potentials in spinal cord hemisection. Am J Phys Med Rehabil. 1989. 68:59–65.

12. Colpi GM, Fanciullacci F, Beretta G, Negri L, Zanollo A. Evoked sacral potentials in subjects with true premature ejaculation. Andrologia. 1986. 18:583–586.

13. Giuliano F, Clément P. Serotonin and premature ejaculation: from physiology to patient management. Eur Urol. 2006. 50:454–466.

14. Waldinger MD, Schweitzer DH. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part I-validity of DSM-IV-TR. J Sex Med. 2006. 3:682–692.

15. Waldinger MD. Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int. 2004. 93:201–207.

16. Gurkan L, Oommen M, Hellstrom WJ. Premature ejaculation: current and future treatments. Asian J Androl. 2008. 10:102–109.

17. Masters WH, Johnson VE. Human sexual inadequacy. 1970. 1st ed. Boston: Little Brown;467.

18. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999. 281:537–544.

19. Fisher S, Osofsky H. Sexual responsiveness in women: physiological correlates. Psychol Rep. 1968. 22:215–226.

20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Text revision DSM-IV-TR. 2000. 4th ed. Washington DC: American Psychiatric Association.

21. St Lawrence JS, Madakasira S. Evaluation and treatment of premature ejaculation: a critical review. Int J Psychiatry Med. 1992. 22:77–97.

22. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. 1993. Geneva (IL): World Health Organization.

23. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994. 151:1377–1379.

24. Waldinger MD. The need for a revival of psychoanalytic investigations into premature ejaculation. J Mens Health Gender. 2006. 3:390–396.

25. McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I, et al. An evidence-based definition of lifelong premature ejaculation: report of the international society for sexual medicine ad hoc committee for the definition of premature ejaculation. BJU Int. 2008. 102:338–350.

26. Semans JH. Premature ejaculation: a new approach. South Med J. 1956. 49:353–358.

27. Johnson VE, Masters WH. A team approach to the rapid diagnosis and treatment of sexual incompatibility. Pac Med Surg. 1964. 72:371–375.

28. Clarke M, Parry L. Premature ejaculation treated by the dual sex team method of Masters and Johnson. Aust N Z J Psychiatry. 1973. 7:200–205.

29. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004. 16:369–381.

30. Althof SE, Levine SB, Corty EW, Risen CB, Stern EB, Kurit DM. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry. 1995. 56:402–407.

31. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998. 18:274–281.

32. Kara H, Aydin S, Yücel M, Agargün MY, Odabaş O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996. 156:1631–1632.

33. Novaretti JP, Pompeo AC, Arap S. Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Braz J Urol. 2002. 28:116–122.

34. Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002. 14:502–505.

35. Segraves RT, Saran A, Segraves K, Maguire E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther. 1993. 19:198–200.

36. Haensel SM, Rowland DL, Kallan KT. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol. 1996. 156:1310–1315.

37. Strassberg DS, de Gouveia Brazao CA, Rowland DL, Tan P, Slob AK. Clomipramine in the treatment of rapid (premature) ejaculation. J Sex Marital Ther. 1999. 25:89–101.

38. Kim SW, Paick JS. Short-term analysis of the effects of as needed use of sertraline at 5 PM for the treatment of premature ejaculation. Urology. 1999. 54:544–547.

39. McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol. 1999. 161:1826–1830.

40. Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res. 2001. 13:41–45.

41. Chia S. Management of premature ejaculation-a comparison of treatment outcome in patients with and without erectile dysfunction. Int J Androl. 2002. 25:301–305.

42. Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol. 2002. 168:2486–2489.

43. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006. 368:929–937.

44. Andersson KE, Mulhall JP, Wyllie MG. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. BJU Int. 2006. 97:311–315.

45. Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998. 92:111–118.

46. Xin ZC, Choi YD, Rha KH, Choi HK. Somatosensory evoked potentials in patients with primary premature ejaculation. J Urol. 1997. 158:451–455.

47. Fanciullacci F, Colpi GM, Beretta G, Zanollo A. Cortical evoked potentials in subjects with true premature ejaculation. Andrologia. 1988. 20:326–330.

48. Xin ZC, Chung WS, Choi YD, Seong DH, Choi YJ, Choi HK. Penile sensitivity in patients with primary premature ejaculation. J Urol. 1996. 156:979–981.

49. Perretti A, Catalano A, Mirone V, Imbimbo C, Balbi P, Palmieri A, et al. Neurophysiologic evaluation of central-peripheral sensory and motor pudendal pathways in primary premature ejaculation. Urology. 2003. 61:623–628.

50. Rowland DL, Haensel SM, Blom JH, Slob AK. Penile sensitivity in men with premature ejaculation and erectile dysfunction. J Sex Marital Ther. 1993. 19:189–197.

51. Bemelmans BL, Hendrikx LB, Koldewijn EL, Lemmens WA, Debruyne FM, Meuleman EJ. Comparison of biothesiometry and neuro-urophysiological investigations for the clinical evaluation of patients with erectile dysfunction. J Urol. 1995. 153:1483–1486.

52. Paick JS, Jeong H, Park MS. Penile sensitivity in men with premature ejaculation. Int J Impot Res. 1998. 10:247–250.

53. Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia. 2002. 34:356–359.

54. Henry R, Morales A. Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study. Int J Impot Res. 2003. 15:277–281.

55. Choi HK, Xin ZC, Choi YD, Lee WH, Mah SY, Kim DK. Safety and efficacy study with various doses of SS-cream in patients with premature ejaculation in a double-blind, randomized, placebo controlled clinical study. Int J Impot Res. 1999. 11:261–264.

56. Choi HK, Jung GW, Moon KH, Xin ZC, Choi YD, Lee WH, et al. Clinical study of SS-cream in patients with primary premature ejaculation. Korean J Urol. 1999. 40:506–511.

57. Henry R, Morales A, Wyllie MG. TEMPE: Topical Eutectic-Like Mixture for Premature Ejaculation. Expert Opin Drug Deliv. 2008. 5:251–261.

58. Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int. 2007. 99:369–375.

59. Morales A, Barada J, Wyllie MG. A review of the current status of topical treatments for premature ejaculation. BJU Int. 2007. 100:493–501.

60. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol. 2007. 52:1331–1339.

61. Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology. 2003. 61:197–200.

62. Fein RL. Intracavernous medication for treatment of premature ejaculation. Urology. 1990. 35:301–303.

63. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med. 2008. 5:188–193.

64. Sadeghi-Nejad H, Watson R. Premature ejaculation: current medical treatment and new directions (CME). J Sex Med. 2008. 5:1037–1050.

65. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int. 2008. 80:162–165.

66. Hosseini MM, Yarmohammadi H. Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int. 2007. 79:28–32.

67. Metin A, Kayigil O, Ahmed SI. Does lidocaine ointment addition increase fluoxetine efficacy in the same group of patients with premature ejaculation? Urol Int. 2005. 75:231–234.

68. You HS. The partial neurectomy of the dorsal nerve of the penis for patients with premature ejaculation. Korean J Androl. 2000. 18:143–148.

69. Kim JJ, Kwak TI, Jeon BG, Cheon J, Moon DG. Effects of glans penis augmentation using hyaluronic acid gel for premature ejaculation. Int J Impot Res. 2004. 16:547–551.